Provided by Tiger Fintech (Singapore) Pte. Ltd.

PAVmed

0.6600
+0.05048.27%
Post-market: 0.66000.00000.00%19:13 EDT
Volume:306.50K
Turnover:191.12K
Market Cap:7.31M
PE:1.25
High:0.6700
Open:0.5913
Low:0.5900
Close:0.6096
Loading ...

PAVmed Regains Compliance With Nasdaq Stockholders' Equity Requirement

THOMSON REUTERS
·
18 Feb

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

PR Newswire
·
18 Feb

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

PR Newswire
·
06 Feb

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

PR Newswire
·
13 Jan

Lucid Inks New Partnership With VITALExam: Stock to Gain?

Zacks
·
26 Dec 2024

Lucid Diagnostics Secures 180-Day Extension to Regain Compliance With Nasdaq Listing Rules

MT Newswires Live
·
24 Dec 2024

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

THOMSON REUTERS
·
23 Dec 2024

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

PR Newswire
·
23 Dec 2024

PAVmed files $125M mixed securities shelf

TIPRANKS
·
21 Dec 2024

BRIEF-Pavmed Inc Files For Mixed Shelf Offering Of Up To $125 Million

Reuters
·
21 Dec 2024

PAVmed Inc: Files for Mixed Shelf Offering of up to $125 Mln

THOMSON REUTERS
·
21 Dec 2024

Lucid Diagnostics partners for esophageal precancer detection for firefighters

TIPRANKS
·
19 Dec 2024

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

PR Newswire
·
19 Dec 2024

Lucid announces publication on EsoGuard in peer-reviewed journal Medicina

TIPRANKS
·
11 Dec 2024

Prospective Clinical Utility Study of Lucid Diagnostics' Esoguard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

THOMSON REUTERS
·
11 Dec 2024

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

PR Newswire
·
11 Dec 2024